ACVR2B and neoplasm: We showed in this study that the type I receptor ALK4 was selectively expressed in ALDHbright CICs along with the type II receptor ActRIIB and ActRIIB and that the shRNA-mediated knockdown of ALK4 significantly inhibited tumor growth in immunodeficient mice.